Search
Close this search box.
Search
Close this search box.
Search
Close this search box.

Be Active in the “Inner Beauty” Movement: Discover VERISOL® byGELITA at in-cosmetics Global 2026

At this year’s in-cosmetics global, GELITA invites visitors to “Be Active!” and experience the science behind Beauty from Within. From April 14 – 16, 2026, in Paris, GELITA will showcase its proven Bioactive Collagen Peptides brand VERISOL® in the new “Inner Beauty” area (Booth 2R140).

As consumer demand for natural and evidence-based beauty solutions continues to rise, Beauty from Within has become one of the most dynamic segments in the personal care and nutricosmetics markets. VERISOL® provides beauty brands with a clinically supported ingredient to power formulations that promote visibly improved skin elasticity, stronger hair, and healthier nails—from the inside out.
Developed specifically for Beauty from Within applications, VERISOL® stimulates extracellular collagen matrix metabolism in the skin through targeted Bioactive Collagen Peptides.
Multiple scientific studies demonstrate its efficacy with a daily dose of only 2.5g and make it “The Gold Standard” in this category. Therefore VERISOL® is the ideal choice for brands seeking to differentiate their product portfolios with reliable results and strong consumer appeal.


At in-cosmetics global 2026, GELITA experts will be on hand to discuss how VERISOL® can support innovation projects in the cosmetics, personal care, nutricosmetics, and supplements sectors. Visitors to booth 2R140 can explore the science, application concepts, and marketing potential of this unique ingredient – and learn how to make their formulations stand out in the growing Inner Beauty market.


Be active. Be beautiful. From within. Visit GELITA at Booth 2R140.

Share the Post:

Related Posts

Advanced CBD Formulations: Personalized Approaches in Hypertension and Sex-Specific Absorption Insights

This review examines cannabidiol (CBD) as a non-psychotropic cannabinoid with growing clinical and nutraceutical relevance. It highlights regulatory-approved CBD medicines and focuses on novel lipid-based formulations designed to improve oral bioavailability. Results from two randomized crossover studies demonstrate enhanced absorption, sex-dependent pharmacokinetics, and CYP450 genotype – related metabolic differences using a lipophilic CBD formulation. Improved cardiovascular outcomes and minimal adverse effects were observed. The findings emphasize the importance of personalized dosing, advanced delivery systems, and improved professional education on CBD use.

Author: Ana Batinić, M.pharm, PhD in Toxycology

Read More